Novelos Inks Deal With Hong Kong-Based Lee’s Pharma For Cancer, Hepatitis Compounds
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Novelos Therapeutics signed an exclusive license agreement with Hong Kong-based Lee's Pharmaceutical Dec. 17, with an aim to expand the sales of its cancer and hepatitis compounds - NOV-002 and NOV205 - in the Greater China region